Skip over main navigation
  • Log in
  • Basket: (0 items)
Hadassah Australia Medical Research Collaboration (HAMRC)
  • Facebook
  • Instagram
Donate
Menu
  • About us
    • Who we are
    • Vision, Mission, Purpose
    • Israel
    • Our team
      • Board
      • Scientific Advisory Committee
      • Development Committee
      • Staff
  • Research
    • Current research
    • Need for collaborative research
    • Partnering with Israel
    • Research partnerships
  • Our impact
    • The difference we can make together
    • Year In Review 2020 - Hadassah Australia
  • Get involved
    • Donate
    • Other ways to give
      • Pledge Gifts
      • Gifts in Wills
    • Project Enquiries
  • News and events
    • News
    • Upcoming Events
    • Webinars
    • Current newsletter
  • Admin
    • Log in
  • Basket: (0 items)
  1. About us
  2. Our team
  3. Scientific Advisory Committee

Scientific Advisory Committee

To assist the board to assess high value research projects, our Scientific Advisory Committee, chaired by Alan Liddle, is comprised of prominent experts in medicine, research and higher education sectors.

Prof Jeffrey Zajac AO

Expand

Prof Jeffrey Zajac is Professor and Head of the University of Melbourne, Department of Medicine at Austin Health. He is a Clinical Endocrinologist and General Physician with research interests in molecular endocrinology. He is Chairman of Medicine and Director of the Department of Endocrinology at Austin Health. Prof Zajac trained in Medicine at the University of Melbourne and undertook a PhD in the Department of Medicine, Austin & Repatriation Medical Centre. Following postdoctoral work in the Endocrine Genetics Unit at Massachusetts General Hospital, Boston, he returned to the University of Melbourne initially at Royal Melbourne Hospital and now Austin Health. His research group has embarked on a major research program investigating the effect of androgen deprivation therapy in patients with prostate cancer. These investigations include effects on bone, muscle, cardiovascular risk and metabolic state. He also heads a molecular endocrinology group investigating the androgen receptor using genetically modified mice.

Published: 13th January, 2020

Updated: 2nd November, 2020

Author:

Share this page
  • Email
  • Facebook
  • Twitter

Dr Michal Milgrom-Hoffman

Expand

Dr Michal Milgrom-Hoffman is currently a Research Fellow in the Department of Biochemistry, Latrobe University and a member of the Humbert Cancer biology, cell polarity and tissue architecture research team under Prof Patrick Humbert looking at how cell asymmetry and tissue organization can regulate cancer initiation, progression and metastasis with the ultimate aim to devise therapeutics to help tumours ‘reorganize’ themselves, thereby stopping the cancer’s growth and spread. The team works closely with cancer clinicians, pathologists, immunologists, a geneticist and a crystallographer.

Published: 13th January, 2020

Updated: 2nd November, 2020

Author:

Share this page
  • Email
  • Facebook
  • Twitter

Dr Gabby Goldberg

Expand

Dr Gabby Goldberg is Operations Manager of Synthesis Research and its investee companies Anaxis Pharma and Catalyst Therapeutics – joint ventures with the Walter and Eliza Hall Institute of Medical Research. She has over 15 years’ experience leading translational research. Her PhD with Prof. Richard Boyd at Monash University resulted in several high-impact publications and a multi-centre clinical trial. She went on to do post-doctoral fellowships in translational immunology at Memorial Sloan-Kettering Cancer Center and Baylor Institute of Immunology Research. Upon her return to Australia, she accepted a Senior Research Officer position with Prof. Ian Wicks at the Walter and Eliza Hall Institute. Working on a CSL Ltd. funded project, she undertook and coordinated a preclinical drug development program involving clinical, academic and industry staff. A year after joining the lab, she was awarded an NHMRC Career Development Fellowship (Industry) which afforded her the opportunity to work on secondment at CSL and play an integral role in the research leading up to the IND filing of a novel drug targeting inflammatory diseases.

 

Published: 13th January, 2020

Updated: 2nd November, 2020

Author:

Share this page
  • Email
  • Facebook
  • Twitter

Alan Liddle - Chair

Expand

Alan Liddle has over 30 years' experience in developing and commercialising medical and biological therapeutics and over 30 years’ research & executive management experience in the medical and the biotechnology research sector encompassing immunology and bio-therapeutics for cancer and auto-immune diseases, cardiology, neuroplasticity, the microbiome, regenerative medicine & rehabilitation. Alan is Executive Director of Sangui Bio a company he cofounded in 2014. Sangui is commercialising its discoveries in the role of red blood cells in immune system activation and regulation. Alan co-founded and was CEO & Director of Immune System Therapeutics Ltd from 2001 to 2011. He was also the Founder, CEO & Director of MicroMedical Industries Limited from 1986. He built the company from a start-up to an ASX listed, international provider of medical monitoring and diagnostic products and a developer of artificial heart technologies. Prior to his biomedical career Alan was a neuropsychologist researcher at the University of Sydney specialising in rehabilitation of patients following traumatic brain injuries. He was the co-inventor of the rehabilitation software program: Dynamind3D. Alan holds a BA (Hons) from the University of Sydney and MBA from the University of NSW and is a fellow of the Australian Institute of Company Directors

Published: 18th March, 2021

Author:

Share this page
  • Email
  • Facebook
  • Twitter
Back to top

Showing 10 of 4

Latest

  • Stable Glucose Levels Prolong Life for Diabetics, Hadassah Study Finds

    Stable Glucose Levels Prolong Life for Diabetics, Hadassah Study Finds

    A Hadassah Medical Organization study reveals that adults with diabetes whose glucose levels fluctuate over the course of five years have an increased risk of mortality compared with those whose levels remain stable.

  • Hadassah Develops its own CAR T Therapy to Treat Multiple Myeloma

    Hadassah Develops its own CAR T Therapy to Treat Multiple Myeloma

    “Many of the hospital staff treating me used to be my patients. Now my life is in their hands,” relates Hadassah Medical Organization social worker Tali Rosen. Since Rosen’s job as a Hadassah social worker was a challenging one, she waved away the initial tiredness and aching bones she experienced. When repeated infections became more than a nuisance, she had herself tested. Rosen was diagnosed with multiple myeloma, cancer within the spongy bone marrow.

  • HADASSAH INTERNATIONAL ANNUAL REPORT 2020 – TOGETHER WE LIVE

    HADASSAH INTERNATIONAL ANNUAL REPORT 2020 – TOGETHER WE LIVE

    We are pleased to share with you Hadassah International’s second Annual Report/Year In Review, available in digital format, entitled “Hadassah International – Together We Live”.

  • From Hidden Child During the Holocaust to Hadassah Surgeon

    From Hidden Child During the Holocaust to Hadassah Surgeon

    Dr Shaul Perlberg, age 80, is still practising urology at Hadassah Hospital Mount Scopus, as he has for many years. But it wasn’t until 16 years ago that he decided to reveal the incredible story of his childhood, the reunion with his mother after the Holocaust, their move to Israel, and the way he met the love of his life, Raya.

Most read

  • Dr Phillip Brenner

  • Dr Errol Katz

  • Alan Liddle

  • About us

    About us

    The HAMRC Foundation is a bold new initiative – a multi-centred collaborative research model that brings together the brightest minds from Israel’s Hadassah Hospital and leading research institutions in Australia and internationally to solve some of the most intractable health problems facing the world today.

  • Research partnerships

    In Hadassah Australia's journey to expand research partnerships, we have collaborated with leading Australian health organisations.

  • Dug Pomeroy

  • Prof Jeffrey Zajac AO

  • Ron Finkel AM

  • Get involved

  • Partnering with Israel

    Partnering with Israel

    With every dollar invested in medical research, Australia gains a $3.90 return to the economy. Many countries competing with Australia have increased their investment. Israel currently has the highest spend globally at 4.25 per cent – thus is a powerful partner for research and development. There are other synergies between our countries including a well-known history of collaboration leading to successful outcomes, medically and commercially.

Sign up for our newsletter

Please enter your first name
Please enter your last name
Please enter your email address Please enter a valid email address (e.g. [email protected])

Find us

Registered Office
PO Box 2400
Caulfield
Vic 3161

+61 (3) 9272 5600
[email protected]

Links

  • Sitemap
  • Accessibility
  • Terms & Conditions
  • Privacy Policy

Follow us

  • Facebook
  • Instagram

Registered as Charity number 90629423641